Abstract
The COVID-19 pandemic has accelerated unprecedented research of experimental treatments as well as using established drugs in new ways. At the end of November 2020, we reflected on the various therapies for COVID-19 that had received regulatory full or emergency use authorisation including the convalescent plasma-derived IgG1 antibodies, bamlanivimab, and the casirivimab-imdevimab cocktail, that provide passive immunity in patients with mild to moderate disease who are at risk for severe illness, the intravenous antiviral, remdesivir, for patients with severe disease requiring hospitalisation, as well as the WHO-endorsed systemic inexpensive glucocorticoids such as dexamethasone, hydrocortisone, methylprednisolone or prednisone for critically ill patients requiring oxygen.1
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
